Business Wire

Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up

9.10.2026 15:15:00 CEST | Business Wire | Press Release

Share

Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements.

Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The valve features the company’s FREE next generation tissue treatment addressing the two main causes of calcification, phospholipids and aldehydes. Its proprietary LANCELOT advanced manufacturing process includes zero-pressure shaping and laser cutting of the pericardium to optimize valve performance and consistency.

“This large study provides the longest clinical follow-up currently reported for the Perceval Plus valve and its FREE tissue technology, offering valuable insights into their sustained clinical and hemodynamic performance over time,” said lead author Michael Ibrahim, MD, PhD, at the University of Virginia Health University Medical Center. “These data demonstrate a favorable hemodynamic profile, characterized by durably low transvalvular gradients and minimal paravalvular regurgitation, along with low rates of reintervention and permanent pacemaker implantation. The high freedom from structural valve deterioration and valve-related reintervention observed during follow-up demonstrates an excellent mid-term durability profile.”

The study presented at EACTS is a sub-analysis including 708 patients treated with Perceval Plus in routine clinical practice at 45 centers as part of the company’s ongoing MANTRA study, a prospective multicenter international registry. The sub-analysis includes many patients reaching 7-year follow-up and is currently enrolling patients.

Highlights from the Perceval Plus sub-analysis include:

  • 99.7% freedom from structural valve deterioration (SVD) from 3 to 7 years
  • 96.6% freedom from aortic valve reoperation from 4 to 7 years
  • 3.7% permanent pacemaker implantation (PPI) rate at 30 days
  • Quality of life improvements:
    • 96.3% of patients classified as NYHA class I-II at 30 days (a 32% improvement from baseline), with more than 95% of patients sustaining that status at 3 year follow-up
    • 19% improvement in mean KCCQ-12 scores from baseline at 30 days (59.6 23.3 to 72.8 22.1), substantially increasing to 31% improvement from baseline at 1 year (59.6 23.3 to 85.4 17.6)
    • 11% improvement in mean EQ-5D-5L VAS scores from baseline at 30 days (65.2 20.2 to 72.7 17.3), increasing to 18% improvement from baseline at 1 year (65.2 20.2 to 79.3 14.8)

In addition to the oral presentation, Perceval Plus is featured in six e-Posters and a Mini-Access Multi-Procedure at EACTS. To view the complete schedule of Perceval Plus and Corcym presentations in the scientific program, click here.

Also at EACTS, Corcym is launching two new devices in its Memo portfolio: TriMemo and Memo 4D Curve, both of which recently celebrated FDA clearance and first-in-human procedures in the U.S. TriMemo is the first device capable of delivering true three-dimensional physiologic motion to the tricuspid valve, and the first tricuspid device to leverage proprietary Memo technology. Memo 4D Curve is a nitinol-based, semi-rigid mitral annuloplasty device with an open configuration, giving surgeons who prefer an open ring access to the three-dimensional motion preservation capability of the Memo platform.

Corcym is exhibiting at EACTS Booth #30 at the International Barcelona Convention Center (CCIB).

“Our commitment to the cardiac surgeon is absolute, and as the specialty evolves, we are leading the way in preparing surgeons to uplevel their skills in order to confidently move into MICS and robotic surgery,” said Christian Mazzi, Chief Executive Officer of Corcym.

“As the only sutureless, collapsible surgical aortic valve, Perceval Plus is at the core of this transition. We are surrounding our innovative product offerings with new technologies, such as the CRIMSON AI-assisted CT analysis platform for aortic valve replacement planning, and our Corcym Academy, focused on training the Surgeons of the Future, to ensure that cardiac surgery remains at the forefront in improving patient lives.”

About Corcym

Corcym is the only global medical device company dedicated to cardiac surgeons, providing the best solutions to help their patients fight structural heart disease. Founded on five decades of trusted partnerships with cardiac surgeons and a comprehensive portfolio of structural heart solutions, Corcym’s innovative technologies offer surgeons a wide range of repair and replacement options for both open-heart and minimally invasive cardiac surgery techniques. https://www.corcym.com/ .

High-resolution product images and additional materials are available upon request.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261009199827/en/

Contacts

MEDIA CONTACTS:

Agency:
Michelle McAdam, Chronic Communications, Inc.
M: 1 310 902 1274
michelle@chronic-comm.com

CORCYM:
Giorgia Cannizzaro, Global Product Specialist & Communications, CORCYM
M: +39 3420460615
giorgia.cannizzaro@corcym.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CORRECTING and REPLACING Yamaha to Acquire Disguise, Expanding Its Capabilities in Integrated Audio, Video, Lighting and Media13.11.2026 18:10:00 CET | Press Release

Please replace the release issued Nov. 12, 2026, at 11:00 p.m. PT/Nov. 13, 2026, at 2:00 a.m. ET with the following corrected version due to multiple revisions in the third paragraph. This release has been updated to ensure the accuracy of certain references in the original version. The updated release reads: YAMAHA TO ACQUIRE DISGUISE, EXPANDING ITS CAPABILITIES IN INTEGRATED AUDIO, VIDEO, LIGHTING AND MEDIA Acquisition combines Yamaha’s audio expertise with Disguise’s software and media server technologies Yamaha Corporation today announced an agreement to acquire Disguise Technologies Limited (“Disguise”), a London-based provider of software and media server technologies for live and immersive experiences. Yamaha will acquire the company by purchasing all shares in its parent, Butterfly Topco Limited. The acquisition will expand Yamaha’s capabilities beyond audio into integrated audio, video, lighting and media solutions, in line with its strategy to expand beyond hardware into soft

VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 17:32:00 CET | Press Release

VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware of the promotion and sale of vehicles that it believes were produced in violation of its intellectual property rights. White s.r.o. therefore decided to take direct action in China, entrusting the protection of its rights to Shanghai-based

LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 16:53:00 CET | Press Release

LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and CEO of LangChain. "Every company should be free to choose the best models for its needs, control its data a

Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press Release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurrent platform is the right foundation for that. Operational orchestration builds on it by connecting planning, decisions and ex

SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press Release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medical was $16 million, up 22% year-over-year. Net income margin was 27%, a decrease of 3 percentage points year-over-year. Adjusted EBITDA1 was $28 million, up 66% year-over-year. Adjusted EBITDA margin1 expanded 9 percentage points year-over-year to 47%. Basic earnings per share (EPS) was $0.15, u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye